The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 27, 2017

Filed:

Jun. 28, 2011
Applicants:

Chae OK Yun, Seoul, KR;

A-rum Yoon, Gyeonggi-do, KR;

Inventors:

Chae Ok Yun, Seoul, KR;

A-Rum Yoon, Gyeonggi-do, KR;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/86 (2006.01); A61K 35/761 (2015.01); C12N 15/85 (2006.01);
U.S. Cl.
CPC ...
C12N 15/85 (2013.01); A61K 35/761 (2013.01); C12N 15/86 (2013.01); C12N 2710/10332 (2013.01); C12N 2710/10343 (2013.01); C12N 2710/10345 (2013.01); C12N 2810/6018 (2013.01); C12N 2830/002 (2013.01); C12N 2830/008 (2013.01); C12N 2830/15 (2013.01); C12N 2830/85 (2013.01);
Abstract

The present invention relates to a gene expression regulating sequence consisting of a combination of HRE, E2F and TERT, and to a gene delivery system having significantly improved selective tumor cell cytotoxicity using same, and more particularly, to a recombinant adenovirus. In addition, the present invention relates to a pharmaceutical antitumor composition comprising the recombinant adenovirus. The replication of the recombinant adenovirus of the present invention is tumor-specifically regulated by the novel gene expression regulating sequence of the present invention, thus enabling the recombinant adenovirus of the present invention to exhibit improved selective tumor cell cytotoxicity or apoptotic potential, and exhibit remarkably improved antitumor effects particularly in hypoxic conditions. In addition, the specific expression of the recombinant adenovirus in tumor cells may increase in vivo stability, and thus may induce greatly improved antitumor effects.


Find Patent Forward Citations

Loading…